Long-term thiethylperazine treatment in the Tg4-42 mouse model of Alzheimer's disease mouse: Therapeutic potential vs. adverse effects
Although thiethylperazine offers mild cognitive benefits in Tg4-42, its adverse effects on learning strategies and locomotion raise questions about its potential as a therapeutic option for AD.
Authors
- Irina Wanda Helene Bänfer
- Jens Wiltfang (ORCID: https://orcid.org/0000-0003-1492-5330)
- Yvonne Bouter (ORCID: https://orcid.org/0009-0002-3893-598X)
- Daniel Liedtke (ORCID: https://orcid.org/0000-0003-0934-7169)
- Thomas A. Bayer (ORCID: https://orcid.org/0000-0001-8453-228X)
- Sofie Elena China
- Friederike Spandau
- Nicola Beindorff (ORCID: https://orcid.org/0000-0001-9126-3356)
- Caroline Bouter (ORCID: https://orcid.org/0000-0002-0057-5037)
- SörenF Bock
- Lisa Katharina Ruoff
Institutions
- German Center for Neurodegenerative Diseases (DE)
- Universitätsmedizin Göttingen (DE)
- University of Göttingen (DE)
- Charité - Universitätsmedizin Berlin (DE)
Publication Details
- Journal
- Pharmacology Biochemistry and Behavior
- Published
- 2025-11-09
- DOI
- https://doi.org/10.1016/j.pbb.2025.174127
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00